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Editor- 
The coronavirus disease-19 (COVID-19), associated with severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly since the early cases 
identified in Wuhan, China, with over 8,061,550 laboratory-confirmed COVID-19 cases 
worldwide and 84,867 patients in China, as of 18th June 2020 1, 2. Among the latter, 19% 
were severe or critically ill cases, who required some form of respiratory support due 
to hypoxaemia or respiratory failure 3. The respiratory support ranged from low-flow 
or high-flow oxygen therapy via nasal cannula or mask; non-invasive or invasive 
positive pressure ventilation; to extracorporeal membrane oxygenation. Considering 
the potential of the COVID-19 pandemic to overwhelm healthcare systems, even in 
developed countries, there is a need to identify subgroups requiring different 
respiratory support techniques, as well as those requiring prolonged hospital 
admission, to inform service provision, allocate scarce medical resources appropriately 
and maximize treatment benefits. Previous studies have reported that older age and 
male gender were risk factors for poor prognosis in COVID-19 patients, with limited 
information about the need for respiratory support 4, 5. A recent study has found that 
high levels of respiratory complications in COVID19 patients requiring surgery, with an 
associated high mortality 6.  
We have retrospectively reviewed demographic and clinical data available from 
electronic medical records at a branch of Tongji Hospital (Wuhan, China), a 1,050 bed 
hospital designated for severe and critically ill COVID-19 patients. This was approved 
by Tongji Hospital Ethics Commission with the need for patients' written informed 
consent waived. Diagnosis and treatment of COVID-19 were performed according to 
the protocol released by China’s National Health Commission 7. Since the outbreak of 
COVID-19 in China, the Chinese National Health Commission has published and 
updated "Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and 
Treatment”. The guidance outlined recommendations for general treatment, as well 
as treatment of severe and critically ill cases. This guidance was adopted as hospital 
policy, with a requirement to follow this, although it is a limitation that we have not 
reviewed all medical records to confirm adherence for every patient. Possible 
treatments included antiviral medications, antibacterial medications, human 
immunoglobulin, steroids and traditional Chinese medicine. For patients with partial 
pressures of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) between 200 
mmHg and 300 mmHg, low-flow or high-flow oxygen therapy via nasal cannula or mask 
was started. For patients with PaO2/FiO2 between 150 mmHg and 200 mmHg, or who 
did not respond to high flow oxygen therapy in the first 2 hours, non-invasive positive 
pressure ventilation was considered. If symptoms worsened or the PaO2/FiO2 was < 
150mmHg, invasive mechanical ventilation was implemented as soon as possible. 
When the patient’s PaO2/FiO2 was < 80mmHg for more than 3 hours, with FiO2 > 90% 
or the airway platform pressure ≥ 35cmH2O, even after lung protective ventilation and 
prone position ventilation were performed, extracorporeal membrane oxygenation 
was used. The highest level of respiratory support required during hospitalisation is 
reported here.  
A total of 1,792 patients hospitalised with COVID-19 between January 27, 2020, 
and April 20, 2020, were consecutively included. Median age was 62 years 
(interquartile range, 51-70; range, 0-95 years) and 48.4% of them were females (Table 
1). Of the included 1,792 patients, 72 (4.0%) patients were admitted from the 
emergency department and 1,720 (96.0%) patients were transferred from other 
hospitals. On admission, most cases were classified as severe (79.9%; ie, respiratory 
frequency ≥ 30/min, blood oxygen saturation at rest ≤ 93%, PaO2/FiO2 ≤ 300 mmHg, 
or increased lung infiltration >50% within 48 hours) or critical (14.0%; ie, shock, 
respiratory failure or other organ or failure). Only 109 (6.1%) cases were moderate (ie, 
having symptoms and radiological findings of pneumonia, with no requirement for 
respiratory support). The percentage of patients who were categorised as critical cases 
on admission was higher in the male groups and older groups. 
Among all patients, high-flow nasal cannula oxygen therapy, non-invasive positive 
pressure ventilation and invasive positive pressure ventilation were given to 60 (3.3%), 
135 (7.5%), 104 (5.8%) patients, respectively, with increased requirement for this 
amongst male and older patients. Extracorporeal membrane oxygenation was given to 
10 (0.6%) patients and 8 (80.0%) of them were male patients. 
The overall case-fatality rate (CFR) was 12.7% (228 deaths among 1,792 confirmed 
cases) and the median of length of stay among deceased patients was 11 days 
(interquartile range, 6-20). CFR was elevated among male patients and groups with 
increasing age. Among surviving patients, 22 (1.2%) were transferred to other 
hospitals to treat comorbidities after recovery from pneumonia and 1,542 (86.0%) 
patients were discharged to the isolation centres for 14 days of quarantine. The length 
of stay among patients discharged was age dependent increasing from 22 
(interquartile range, 14-31.3) days in those aged under 40 to 34 (interquartile range, 
24-43.8) days in those aged 80 or over. Of the 1,542 patients who were discharged, 
514 (33.3%) still required low-flow oxygen therapy at discharge and the requirement 
increased with age. 
A strength of the current study is the size of the cohort of COVID-19 patients 
requiring respiratory support we report on. This data, from a single centre in Wuhan, 
provide insights into sex-specific and age-related factors. The findings in this study 
could be a useful supplement to previous studies about morbidity and mortality from 
COVID-19 3, 8, 9, to help inform allocation of scarce health care resources (especially 
respiratory support) and mitigation of adverse effects of the COVID-19 pandemic in 
other countries. Furthermore, one third of COVID-19 patients had abnormal 
pulmonary function at time of hospital discharge with a higher percentage in older 
patients. Our results are consistent with the findings of a previous study, which found 
that 84.2% of severe cases with COVID-19 were discharged with impairment of 
diffusion capacity 10. Future studies to address persistent impairment of pulmonary 
function of COVID-19 and the impact of age are warranted. 
A limitation with our study is that the adherence to the national COVID-19 
guidelines might be varied in individual patients, and therefore we are unable to assess 
the standard of management applied. While our impression is that adherence was 
rigorous, we plan to assess this as part of the future research with this cohort. Another 
limitation is that extraction of other relevant patient level data was restricted, such 
that more extensive analyses were not possible within the timescale and resources 
available. This highlights the challenges in rapidly developing a high quality evidence 
base, in the midst of a global pandemic. Limitations of existing healthcare data systems 
(eg paper medical records, no facility to efficiently extract data from individual records, 
etc), lack of appropriately trained personnel, as staff diverted to dealing with acute 
crisis, and the impact of lockdown on collaborative working are all barriers that need 
to be considered.    
Despite these issues, we believe that it is important to report this data, as an 
incremental addition to the evolving evidence base. It is clear from this, that that 
health and social care provision, for both acute care and postCOVID-19 management, 
may need to be realigned. Understanding the factors that impact on research in global 
challenges such as COVID-19, is important when urgent good quality clinical guidance 
is needed. As we move forwards, perhaps one of the key learning points is to consider 
how, as a global research community, we can work most effectively together.  
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Table 1 Demographic and clinical characteristics of patients with COVID-19. 
 













Spectrum of disease        
Moderate 109 (6.1) 59 (6.4) 50 (5.8) 14 (6.7) 38 (6.7) 48 (5.5) 9 (6.0) 
Severe 1,432 (79.9) 712 (77.1) 720 (82.9) 181(87.0) 470 (82.7) 674 (77.8) 107 (71.3) 
Critical 251 (14.0) 153 (16.6) 98 (11.3) 13 (6.3) 60 (10.6) 144 (16.6) 34 (22.7) 
Respiratory support during 
hospitalisationa 
       
No 247 (13.8) 126 (13.6) 121 (13.9) 56 (26.9) 98 (17.3) 90 (10.4) 3 (2.0) 
LFNC 1,133 (63.2) 553 (59.8) 580 (66.8) 133 (63.9) 373 (65.7) 539 (62.2) 88 (58.7) 
LFM 77 (4.3) 41 (4.4) 36 (4.1) 5 (2.4) 20 (3.5) 39 (4.5) 13 (8.7) 
HFNC 60 (3.3) 41 (4.4) 19 (2.2) 3 (1.4) 15 (2.6) 33 (3.8) 9 (6.0) 
NIPPV 135 (7.5) 84 (9.1) 51 (5.9) 1 (0.5) 29 (5.1) 86 (9.9) 19 (12.7) 
IPPV 104 (5.8) 57 (6.2) 47 (5.4) 4 (1.9) 22 (3.9) 63 (7.3) 15 (10.0) 
ECMO 10 (0.6) 8 (0.9) 2 (0.2) 0 (0) 6 (1.1) 4 (0.5) 0 (0) 
Outcomes        
Discharged 1,542 (86.0) 760 (82.3) 782 (90.1) 201 (96.6) 520 (91.5) 716 (82.7) 105 (70.0) 
Died 228 (12.7) 150 (16.2) 78 (9.0) 5 (2.4) 42 (7.4) 138 (15.9) 42 (28.0) 
Transferred 22 (1.2) 14 (1.5) 8 (0.9) 2 (1.0) 5 (0.9) 12 (1.4) 3 (2.0) 











































Respiratory support at 
dischargec 
       
No 1,006 (65.2) 495 (65.1) 511 (65.3) 173 (86.1) 344 (66.2) 434 (60.6) 55 (52.4) 
LFNC or LFM 514 (33.3) 256 (33.7) 258 (33.0) 28 (13.9) 168 (32.3) 270 (37.7) 48 (45.7) 
 
Data are presented as median (interquartile range) or n (%). 
COVID-19, the coronavirus disease-19; LFNC, Low-flow nasal cannula oxygen therapy; LFM, 
Low-flow mask oxygen therapy; HFNC, high-flow nasal cannula oxygen therapy; NIPPV, 
non-invasive positive pressure ventilation; IPPV, invasive positive pressure ventilation; ECMO, 
extracorporeal membrane oxygenation. 
a Only the highest level of respiratory support during hospitalisation is presented. 
b Transfers from one hospital to another were merged. 
c Only patients who were discharged were included. 
 
 
 
 
 
 
 
